Published in Vet World on January 29, 2016
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2005) 6.04
The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer (2004) 5.47
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
Vascular endothelial growth factor and angiogenesis. Pharmacol Rev (2004) 5.41
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 5.29
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res (2005) 4.21
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J (1998) 4.14
Protein-tyrosine phosphatases and cancer. Nat Rev Cancer (2006) 3.65
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther (2005) 3.28
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) (2005) 2.89
Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer (2001) 2.69
EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol (2005) 2.37
Targeted therapies: a new generation of cancer treatments. Am Fam Physician (2008) 2.36
Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem (2002) 2.17
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene (1998) 2.03
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol (2007) 1.96
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry (2006) 1.96
Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol (2010) 1.96
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic (2001) 1.89
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst (2012) 1.86
Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol (2008) 1.82
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci (2010) 1.78
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol (2012) 1.77
Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene (2004) 1.77
Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol (2006) 1.69
Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A (2003) 1.66
Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev (2001) 1.65
Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol (2001) 1.58
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Endocytosis of receptor tyrosine kinases. Cold Spring Harb Perspect Biol (2013) 1.57
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer (2010) 1.56
Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med (2011) 1.51
Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol (1998) 1.49
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol (2013) 1.46
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med (2009) 1.33
The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist (2008) 1.32
Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol (2005) 1.30
Tyrosine kinase - Role and significance in Cancer. Int J Med Sci (2004) 1.26
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control (2002) 1.25
Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol (2011) 1.24
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol (2011) 1.24
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther (2008) 1.23
Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev Genes Evol (2001) 1.22
Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med (2013) 1.21
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood (2006) 1.20
Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int (2001) 1.20
Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem (2009) 1.19
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res (2010) 1.18
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst (2014) 1.17
A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology (2006) 1.15
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res (2009) 1.13
VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist (2005) 1.13
The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med (2011) 1.12
Recent advances in cancer therapy: an overview. Curr Pharm Des (2010) 1.10
Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene (2009) 1.09
VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J (2001) 1.09
Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci (2004) 1.08
FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol (2009) 1.04
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A (2014) 1.04
Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs (2008) 1.04
Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res (2009) 1.03
Bevacizumab (Avastin). AJNR Am J Neuroradiol (2009) 1.03
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res (2011) 1.03
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol (2011) 1.02
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene (2009) 1.01
Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J (2013) 1.00
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther (2013) 0.99
Signal transduction therapy of cancer. Mol Aspects Med (2010) 0.98
PDGF: the nuts and bolts of signalling toolbox. Tumour Biol (2011) 0.97
Targeting insulin-like growth factor signaling: rational combination strategies. Mol Cancer Ther (2010) 0.97
Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface? J Clin Oncol (2013) 0.96
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma (2012) 0.95
Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS One (2013) 0.95
Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol (2010) 0.93